The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Affiliations

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Neurology, Medstar Georgetown University Hospital, Washington, District of Columbia, USA.
³ Department of Neurology, Weill Cornell Medicine, New York, New York, USA.

Comment

Rebecca C Burch et al. Headache. 2022 Jan.

. 2022 Jan;62(1):111-112.

doi: 10.1111/head.14245. Epub 2021 Dec 7.

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Neurology, Medstar Georgetown University Hospital, Washington, District of Columbia, USA.
³ Department of Neurology, Weill Cornell Medicine, New York, New York, USA.

No abstract available

Keywords: American Headache Society; behavioral; calcitonin gene related peptide; consensus statement; migraine; neuromodulation.

Comment on

Hypertension: A new safety risk for patients treated with erenumab.
Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Saely S, et al. Headache. 2021 Jan;61(1):202-208. doi: 10.1111/head.14051. Epub 2021 Jan 10. Headache. 2021. PMID: 33423274

1. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18. doi:10.1111/head.13456. Erratum in: Headache. 2019;59(4):650-651.
1. Tfelt-Hansen P, Loder E. The emperor's new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019;59(1):113-117. doi:10.1111/head.13444
1. Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021;325(18):1874-1885. doi:10.1001/jama.2021.1640
1. Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD. Anti-CGRP monoclonal antibodies for migraine prevention: a systemic review and likelihood to help or harm analysis. Cephalalgia. 2021;41:851-864.
1. Saely S, Croteau D, Jawidzik L, et al. Hypertension: a new safety risk for patients treated with erenumab. Headache. 2021;61(1):202-208.